CYCN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Cyclerion Therapeutics Inc (CYCN.O) is -0.05, compared to its 5-year average forward P/E of -0.75. For a more detailed relative valuation and DCF analysis to assess Cyclerion Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.75

Current PE

-0.05

Overvalued PE

0.22

Undervalued PE

-1.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.16

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.33

Undervalued EV/EBITDA

-0.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.30

Current PS

0.00

Overvalued PS

22.94

Undervalued PS

-4.34

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CYCN News & Events

Events Timeline

No data

News

6.0

11-10Benzinga

Cycurion Secures Over $1 Million Contract to Upgrade Federal Emergency Warning System

7.5

09-24NASDAQ.COM

What’s Driving the Surge in Cyclerion Stock During Pre-market Trading?

9.0

09-24NASDAQ.COM

Biotech Stocks Rise After Hours Following Trial News and Strategic Developments

People Also Watch

Frequently Asked Questions

What is Cyclerion Therapeutics Inc (CYCN) stock price today?

The current price of CYCN is 1.6 USD — it has increased 5.96 % in the last trading day.

What is Cyclerion Therapeutics Inc (CYCN)'s business?

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

What is the price predicton of CYCN Stock?

Wall Street analysts forecast CYCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYCN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cyclerion Therapeutics Inc (CYCN)'s revenue for the last quarter?

Cyclerion Therapeutics Inc revenue for the last quarter amounts to 875.00K USD, increased 351.03 % YoY.

What is Cyclerion Therapeutics Inc (CYCN)'s earnings per share (EPS) for the last quarter?

Cyclerion Therapeutics Inc. EPS for the last quarter amounts to -0.30 USD, increased 3.45 % YoY.

What changes have occurred in the market's expectations for Cyclerion Therapeutics Inc (CYCN)'s fundamentals?

The market is revising No Change the revenue expectations for CYCN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -34.59%.

How many employees does Cyclerion Therapeutics Inc (CYCN). have?

Cyclerion Therapeutics Inc (CYCN) has 1 emplpoyees as of December 16 2025.

What is Cyclerion Therapeutics Inc (CYCN) market cap?

Today CYCN has the market capitalization of 5.93M USD.